AR067444A1 - Derivados de pirazinona, procesos de obtencion y composiciones farmaceuticas - Google Patents

Derivados de pirazinona, procesos de obtencion y composiciones farmaceuticas

Info

Publication number
AR067444A1
AR067444A1 ARP080102812A ARP080102812A AR067444A1 AR 067444 A1 AR067444 A1 AR 067444A1 AR P080102812 A ARP080102812 A AR P080102812A AR P080102812 A ARP080102812 A AR P080102812A AR 067444 A1 AR067444 A1 AR 067444A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally
alkoxy
aryl
substituted
Prior art date
Application number
ARP080102812A
Other languages
English (en)
Inventor
Timothy Jon Luker
Stephen Brough
Richard Evans
Piotr Raubo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR067444A1 publication Critical patent/AR067444A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1) en la cual R1, R1a y R2 son seleccionados independientemente entre H, alquilo C1-6, alcoxi C1-6, halo, CF3, y CN; R3 y R4 son seleccionados independientemente entre H, alquilo C1-6, alcoxi C1-6, halo, OH, NR8R9, CF3, CN, arilo, heteroarilo y CONR10R11, donde dicho alquilo C1-6 y dicho alcoxi C1-6 opcionalmente están sustituidos independientemente con 1, 2 o 3 grupos que se seleccionan independientemente entre OH, alcoxi C1-3, NR12R13, S(O)pR55 y halo; R5 se selecciona entre arilo, heteroarilo, heterocicloalquilo, cicloalquilo C3-7; (CR14R15)mR16R17, S(O)pR16, SO2NR16R17, CH2R16 y OR16; R6 se selecciona entre H, alquilo C1-6, alcoxi C1-6, cicloalquilo C3-7, -cicloalquil C3-7-alquilo C1-6, heteroarilo y arilo; donde dicho alquilo C1-6 puede estar opcionalmente sustituido con halo o OH; R7 se selecciona entre H, alquilo C1-6, alcoxi C1-6, cicloalquilo C3-7 y arilo; o R6 y R7 junto con el átomo de nitrogeno al que están unidos forman un anillo de entre 4 y 7 miembros, que opcionalmente contiene un heteroátomo adicional que se selecciona entre NR18, S y O; R8 y R9 son seleccionados independientemente entre H, alquilo C1-6, alcoxi C1-6 y cicloalquilo C3-6; o R8 y R9 junto con el átomo de nitrogeno al que están unidos forman un anillo de entre 4 y 7 miembros, que opcionalmente contiene un heteroátomo adicional que se selecciona entre NR19, S y O; R14 y R15 son seleccionados entre H y alquilo C1-6; o R14 y R15 junto con el carbono al que están unidos forman un grupo carbonilo (C=O); R16 se selecciona entre H, arilo, cicloalquilo C3-7 y -C(R22R23)-X-Z, donde dicho cicloalquilo C3-7 opcionalmente puede estar sustituido. con un grupo arilo; R17 se selecciona entre H, alquilo C1-6, arilo, heteroarilo, heterocicloalquilo y cicloalquilo C3-7, donde dicho alquilo C1-6 opcionalmente puede estar sustituido con 1, 2 o 3 grupos que se seleccionan independientemente entre alcoxi C1-6, cicloalquilo C3-10, heterocicloalquilo, heteroarilo y NR20R21; R22 se selecciona entre H, alquilo C1-6, alcoxi C1-6, OH, NR29R30, heterocicloalquilo y arilo, donde dicho alquilo C1-6 opcionalmente puede estar sustituido con 1, 2 o 3 grupos R28 y donde dicho arilo opcionalmente puede estar sustituido con 1 2 o 3 grupos que se seleccionan independientemente entre alquilo C1-6, alcoxi C1-6, halo, CF3 y OH; R23 se selecciona entre H y alquilo C1-6; o R22 y R23 junto con el átomo dé carbono al que están unidos forman un anillo cicloalquilo C3-7 o heterocicloalquilo; X es un enlace o un grupo (CR24R25)n; R24 y R25 son seleccionados independientemente entre H, alquilo C1-6, alcoxi C1-6, OH, heterocicloalquilo y NR39R40; o R24 y R25 junto con el átomo de carbono al que están unidos pueden formar un anillo heterocicloalquilo; Z es un anillo arilo o heteroarilo, donde dicho anillo arilo o heteroarilo está sustituido con R26 y R27; R26 se selecciona entre H, alquilo C1-6, alcoxi C1-6, OH, arilo, O-arilo, halo, heterocicloalquilo, O-heterocicloalquilo, heteroarilo, O-heteroarilo, cicloalquilo, O-cicloalquilo, S(O)pR34, NR34R35 y CONR34R35, donde dicho alquilo C1-6 o dicho alcoxi C1-6 opcionalmente puede estar sustituido con 1, 2 o 3 grupos que se seleccionan independientemente entre halo, OH, heterocicloalquilo o NR34R35; R27 se selecciona entre H, halo y alquilo C1-6, donde dicho alquilo C1-6 opcionalmente puede estar sustituido con 1, 2 o 3 grupos halo; o R26 y R27 juntos pueden formar un grupo metilendioxi, cuando se unen a átomos de carbono adyacentes en el anillo arilo o heteroarilo; cada caso de R28 se selecciona independientemente entre NR29R30, halo, CH2CF3, CF3, heterocicloalquilo, alcoxi C1-6, OR36, COOR42, CONR31R32 y SO2NR37R38; R29 y R30 son seleccionados independientemente entre H, alquilo C1-6, cicloalquilo C3-7, SO2R41 y C(O)R41, donde dicho alquilo C1-6 opcionalmente puede estar sustituido con OH, NR56R57 o heterocicloalquilo; R31 y R32 son seleccionados independientemente entre H, alquilo C1-6 y cicloalquilo C3-7; o R31 y R32 junto con el átomo de nitrogeno al que están unidos forman un anillo de entre 4 y 7 miembros, que opcionalmente contiene un heteroátomo adicional que se selecciona entre NR33, S y O; R34 y R35 son seleccionados independientemente entre H, alquilo C1-6, cicloalquilo C3-7, C-heterocicloalquilo y C(O)O-alquilo C1-6, donde dicho alquilo C1-6 puede estar opcionalmente sustituido con OH, halo, alcoxi C1-6, NR58R59, C(O)OH y heterocicloalquilo; o R34 y R35 junto con el nitrogeno al que están unidos forman un anillo de entre 4 y 7 miembros; R36 se selecciona entre H, alquilo C1-6 y heterocicloalquilo, donde dicho alquilo C1-6 opcionalmente puede estar sustituido con heterocicloalquilo; R10, R11, R12, R13, R18, R19, R20, R21, R33, R37, R38, R39, R40, R41 y R42 son seleccionados independientemente entre H y alquilo C1-6; m es 0 o 1; n es 1 o 2; cada caso de p se selecciona independientemente entre 0, 1 o 2; cicloalquilo es un anillo carbocíclico no aromático, opcionalmente fusionado con un grupo arilo, donde dicho anillo cicloalquilo opcionalmente contiene, de ser posible, hasta 2 enlaces dobles y donde, a no ser que se indique otra cosa, dicho cicloalquilo opcionalmente puede estar sustituido con 1 a 2 sustituyentes que se seleccionan independientemente entre alquilo C1-6, alcoxi C1-6, OH, CN, CF3, halo y NR43R44; heterocicloalquilo es un anillo no aromático, mono o bicíclico de entre 3 y 9 miembros unido a C o unido a N, opcionalmente fusionado a un grupo arilo o heteroarilo, donde dicho anillo heterocicloalquilo contiene 1 o 2 átomos NR45, o un átomo de N-, o un átomo de N- y un NR45, o un átomo de N-, un -NR45 y un S(O)p o un átomo de O, o un átomo de N- y un S(O)p o un átomo de O, o un átomo de S, o un átomo de O; que donde es posible contiene opcionalmente 1 o 2 enlaces dobles; y opcionalmente está sustituido sobre carbono con 1 o 2 sustituyentes que se seleccionan independientemente entre alquilo C1-6, alcoxi C1-6, OH, CN, CF3, halo, =O, NR46R47, -C(O)NR46R47, sustituyente bivalente -OCH2CH2O- (donde los átomos de oxígeno terminales están unidos al mismo átomo de carbono del anillo), sustituyente bivalente -CH2NHCH2- (donde los átomos de carbono terminales están unidos al mismo átomo de carbono del anillo), un grupo tetrahidro-1,1-dioxido-3-tienilo, y arilo, donde dicho alquilo C1-6 puede estar opcionalmente sustituido con arilo, alcoxi C1-6 o OH; y donde cada grupo arilo opcionalmente puede estar sustituido con alcoxi C1-6 (que a su vez puede estar opcionalmente sustituido con NR34R35), alquilo C1-6, OH, CF3 y halo; arilo es un anillo aromático que contiene de 6 a 10 átomos de carbono; donde, a no ser que se indique otra cosa, dicho arilo opcionalmente puede estar sustituido con 1, 2 o 3 sustituyentes que se seleccionan independientemente entre alquilo C1-6, alcoxi C1-6, OH, halo, CN, CF3 y NR48R49; heteroarilo es un anillo aromático de 5, 6, 9 o 10 miembros, que contiene entre 1 o 2 átomos de N y, opcionalmente, un átomo de NR50, o un átomo de NR50 y un átomo de S u O, o un átomo de S, o un átomo de O; donde, a no ser que se indique otra cosa, dicho -heteroarilo opcionalmente puede estar sustituido con 1, 2 o 3 sustituyentes que se seleccionan independientemente entre alquilo C1-6, alcoxi C1-6; OH, halo, CN, CF3 y NR51R52; R45 se selecciona entre H, alquilo C1-6, C(O)alquilo C1-6, C(O)O-alquilo C1-6 y arilo, donde dicho alquilo C1-6 opcionalmente está sustituido con un grupo que se selecciona entre alcoxi C1-3, OH, halo, heterocicloalquilo y NR29R30; y donde dicho C(O)O-alquilo C1-6 opcionalmente está sustituido con un grupo arilo; R50 se selecciona entre H, alquilo C1-6 y C(O)O-alquilo C1-6, donde dicho alquilo C1-6 opcionalmente puede estar sustituido con un grupo que se selecciona entre alcoxi C1-3, OH, halo, cicloalquilo C3-6 y NR53R54; R43, R44, R46, R47, R48, R49, R51, R52, R53, R54, R55, R56, R57 y R59 son seleccionados cada uno independientemente entre H y alquilo C1-6; R58 se selecciona entre H y alquilo C1-6 donde dicho alquilo C1-6 opcionalmente puede estar sustituido con un grupo que se selecciona entre alcoxi C1-3 y OH; o sales de los mismos aceptables para uso farmacéutico.
ARP080102812A 2007-06-27 2008-06-27 Derivados de pirazinona, procesos de obtencion y composiciones farmaceuticas AR067444A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94641507P 2007-06-27 2007-06-27
US97816707P 2007-10-08 2007-10-08
US2944408P 2008-02-18 2008-02-18

Publications (1)

Publication Number Publication Date
AR067444A1 true AR067444A1 (es) 2009-10-14

Family

ID=39745171

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102812A AR067444A1 (es) 2007-06-27 2008-06-27 Derivados de pirazinona, procesos de obtencion y composiciones farmaceuticas

Country Status (31)

Country Link
US (4) US8163905B2 (es)
EP (1) EP2170848B1 (es)
JP (2) JP5140154B2 (es)
KR (1) KR101541203B1 (es)
CN (1) CN101842361B (es)
AR (1) AR067444A1 (es)
AU (1) AU2008269516B2 (es)
BR (1) BRPI0813244B8 (es)
CA (1) CA2691215C (es)
CL (1) CL2008001898A1 (es)
CO (1) CO6251251A2 (es)
CY (1) CY1115836T1 (es)
DK (1) DK2170848T3 (es)
EC (1) ECSP109903A (es)
ES (1) ES2525716T3 (es)
HK (1) HK1142908A1 (es)
HR (1) HRP20141174T1 (es)
IL (1) IL202826A (es)
MY (1) MY153258A (es)
NZ (1) NZ581942A (es)
PE (1) PE20090547A1 (es)
PL (1) PL2170848T3 (es)
PT (1) PT2170848E (es)
RS (1) RS53682B1 (es)
RU (1) RU2479580C2 (es)
SG (1) SG182958A1 (es)
SI (1) SI2170848T1 (es)
TW (1) TWI448288B (es)
UA (1) UA98961C2 (es)
UY (1) UY31183A1 (es)
WO (1) WO2009001132A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY153258A (en) 2007-06-27 2015-01-29 Astrazeneca Ab Pyrazinone derivatives and their use inthe threatment of lung diseases
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
AR073711A1 (es) 2008-10-01 2010-11-24 Astrazeneca Ab Derivados de isoquinolina
EP2361242B1 (en) 2008-10-17 2018-08-01 Oryzon Genomics, S.A. Oxidase inhibitors and their use
US8969350B2 (en) * 2008-12-18 2015-03-03 Astrazeneca Ab Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient
EP2389362B1 (en) 2009-01-21 2019-12-11 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
BR112012006572A2 (pt) 2009-09-25 2016-04-26 Oryzon Genomics Sa inibidores de demetilase-1 de lisina específicos e seu uso
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
EP2519108A4 (en) 2009-12-31 2013-10-16 Ira Milton Trachtman COMPOSITIONS AND METHODS FOR THE TREATMENT AND PROPHYLAXIS OF INFLAMMATORY INTESTINAL DISEASE
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
US9186337B2 (en) 2010-02-24 2015-11-17 Oryzon Genomics S.A. Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
WO2011131697A1 (en) 2010-04-19 2011-10-27 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
EP3375775A1 (en) 2010-07-29 2018-09-19 Oryzon Genomics, S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
TWI535712B (zh) * 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
WO2012107498A1 (en) 2011-02-08 2012-08-16 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative disorders
WO2012156531A2 (en) * 2011-05-19 2012-11-22 Oryzon Genomics, S.A. Lysine demethylase inhibitors for inflammatory diseases or conditions
BR112014009238B1 (pt) 2011-10-20 2022-08-09 Oryzon Genomics S.A. Compostos de (hetero)aril ciclopropilamina, seus usos e composições farmacêuticas
EP2768805B1 (en) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
KR20150000900A (ko) 2012-04-10 2015-01-05 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규한 1-치환된 인다졸 유도체
CA2872110C (en) 2012-07-18 2019-08-06 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US20140302819A1 (en) * 2013-04-05 2014-10-09 Microsoft Corporation Techniques for selecting a proximity card of a mobile device for access
US9790195B2 (en) 2013-08-06 2017-10-17 Imago Biosciences, Inc. KDM1A inhibitors for the treatment of disease
LT3160956T (lt) 2014-06-27 2020-09-10 Celgene Quanticel Research, Inc. Lizinui specifinės demetilazės-1 inhibitoriai
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
KR102626978B1 (ko) 2015-02-12 2024-01-18 이마고 바이오사이언시즈 인코포레이티드 질환 치료를 위한 kdm1a 저해제
KR20180128020A (ko) * 2016-03-24 2018-11-30 아스트라제네카 아베 결정형
WO2017174621A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property (No.2) Limited Pyridyl derivatives as bromodomain inhibitors
WO2018035259A1 (en) 2016-08-16 2018-02-22 Imago Biosciences, Inc. Methods and processes for the preparation of kdm1a inhibitors
WO2018075598A1 (en) * 2016-10-19 2018-04-26 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
CN106674029B (zh) * 2016-12-23 2018-08-21 四川久凌制药科技有限公司 一种他喷他多中间体的制备方法
BR112021001066A2 (pt) * 2018-05-11 2021-04-20 Imago Biosciences, Inc. composto, método de tratamento de uma doença mediada por kdm1a, método de tratamento de uma doença mediada por globina, composição farmacêutica; método de inibição de kdm1a, método para obter um efeito em um paciente, e método para inibir pelo menos uma função de kdm1a
EP4122926A4 (en) * 2021-04-14 2023-08-30 Shionogi & Co., Ltd TRIAZINE DERIVATIVE HAVING AN INHIBITOR EFFECT ON THE PROPAGATION OF VIRUSES, AND PHARMACEUTICAL COMPOSITION CONTAINING IT
CN113999129B (zh) * 2021-11-23 2023-09-01 长沙普济生物科技股份有限公司 一种含酚羟基氨基酸表面活性剂的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181360C2 (ru) * 1996-09-06 2002-04-20 Ниппон Каяку Кабусики Кайся Новые производные ацетамида, способ их получения, фармацевтический состав и ингибиторы протеаз на их основе
TWI328007B (en) 2002-01-16 2010-08-01 Astrazeneca Ab Novel compounds
IL163957A0 (en) 2002-03-14 2005-12-18 Bayer Healthcare Ag Monocyclic aroylpyridinones as antiinflammatory agents
CN1305871C (zh) 2002-07-19 2007-03-21 比奥维特罗姆股份公司 用于治疗与5－ht2a受体有关疾病的新哌嗪基－吡嗪酮衍生物
WO2005033105A2 (en) 2003-09-30 2005-04-14 Amgen Inc. Vanilloid receptor ligands and their use in treatments
BRPI0415390A (pt) * 2003-10-14 2006-12-12 Pharmacia Corp compostos de pirazinona substituìda para o tratamento da inflamação
NZ545694A (en) * 2003-12-03 2010-04-30 Ym Bioscience Australia Pty Lt Azole-based kinase inhibitors
GB0402812D0 (en) * 2004-02-09 2004-03-10 Tanabe Seiyaku Co Novel compounds
EP1763353A1 (en) 2004-06-29 2007-03-21 Warner-Lambert Company LLC COMBINATION THERAPIES UTILIZING BENZAMIDE INHIBITORS OF THE P2X<sb>7</sb> RECEPTOR
JP4496092B2 (ja) 2005-01-12 2010-07-07 信越化学工業株式会社 光ファイバ母材の製造方法及び装置
RU2008129679A (ru) 2005-12-21 2010-01-27 Янссен Фармацевтика Н.В. (Be) Новые замещенные пиразиноновые производные для применения при мсн-1-опосредованных заболеваниях
GB0608837D0 (en) 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of MAP kinase
AU2007246869B2 (en) 2006-05-04 2012-10-18 Macrophage Pharma Limited p38 MAP kinase inhibitors
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
AU2007253299A1 (en) * 2006-05-22 2007-11-29 Janssen Pharmaceutica N.V. Substituted pyrazinone derivatives for use as a medicine
WO2007149448A2 (en) * 2006-06-21 2007-12-27 E. I. Du Pont De Nemours And Company Pyrazinones as cellular proliferation inhibitors
TW200924754A (en) * 2006-06-21 2009-06-16 Du Pont Pyrazinones as cellular proliferation inhibitors
MY153258A (en) 2007-06-27 2015-01-29 Astrazeneca Ab Pyrazinone derivatives and their use inthe threatment of lung diseases

Also Published As

Publication number Publication date
NZ581942A (en) 2012-01-12
CN101842361A (zh) 2010-09-22
US20130012523A1 (en) 2013-01-10
RU2479580C2 (ru) 2013-04-20
PT2170848E (pt) 2014-12-23
US20120214822A1 (en) 2012-08-23
PL2170848T3 (pl) 2015-02-27
IL202826A0 (en) 2010-06-30
BRPI0813244B1 (pt) 2019-03-26
HK1142908A1 (en) 2010-12-17
KR20100038398A (ko) 2010-04-14
CL2008001898A1 (es) 2009-07-17
CY1115836T1 (el) 2017-01-25
TW200908978A (en) 2009-03-01
KR101541203B1 (ko) 2015-07-31
JP5539473B2 (ja) 2014-07-02
UY31183A1 (es) 2009-01-30
SG182958A1 (en) 2012-08-30
SI2170848T1 (sl) 2015-01-30
TWI448288B (zh) 2014-08-11
BRPI0813244B8 (pt) 2021-05-25
WO2009001132A1 (en) 2008-12-31
ECSP109903A (es) 2010-02-26
CA2691215C (en) 2016-03-29
AU2008269516B2 (en) 2011-11-17
JP2013018781A (ja) 2013-01-31
CN101842361B (zh) 2013-06-05
US20120065214A1 (en) 2012-03-15
DK2170848T3 (en) 2015-01-05
EP2170848A1 (en) 2010-04-07
IL202826A (en) 2014-11-30
HRP20141174T1 (hr) 2015-02-13
JP5140154B2 (ja) 2013-02-06
MY153258A (en) 2015-01-29
AU2008269516A1 (en) 2008-12-31
BRPI0813244A2 (pt) 2014-12-23
EP2170848B1 (en) 2014-10-22
CO6251251A2 (es) 2011-02-21
RU2009148673A (ru) 2011-08-10
CA2691215A1 (en) 2008-12-31
UA98961C2 (uk) 2012-07-10
US20150073136A1 (en) 2015-03-12
JP2010531345A (ja) 2010-09-24
US8163905B2 (en) 2012-04-24
US8299246B2 (en) 2012-10-30
RS53682B1 (en) 2015-04-30
PE20090547A1 (es) 2009-06-04
ES2525716T3 (es) 2014-12-29
US8889692B2 (en) 2014-11-18

Similar Documents

Publication Publication Date Title
AR067444A1 (es) Derivados de pirazinona, procesos de obtencion y composiciones farmaceuticas
AR040514A1 (es) Heterociclos diarilicos sustituidos, procedimiento para la preparacion de medicamentos y la utilizacion de los compuestos para tal fin
PE20160751A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6
AR108388A2 (es) Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas
AR084152A1 (es) Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc
AR059458A1 (es) Arildihidroisoquinolinonas sustituidas con azaciclilo, procedimiento para su preparacion y su uso como medicamentos
AR085987A1 (es) Compuestos tri- y tetraciclicos pirazol[3,4-b]piridina como agentes antineoplasicos
AR075402A1 (es) Derivados heterociclicos oxigenados y/o nitrogenados de tetrahidronaftaleno, medicamentos que los contienen y uso de los mismos en el tratamiento de trastornos metabolicos, tales como obesidad,entre otros.
AR058387A1 (es) Bifenilcarboxamidas
AR078797A1 (es) Inhibidores de la caseina quinasa, composiciones farmaceuticas y sus usos para tratar trastornos del snc
DOP2007000022A (es) Derivados de n-heteroaril-carboxamidas tricíclicas que contienen un resto bencimidazol, su preparación y su aplicación en terapéutica
AR061923A1 (es) Compuestos derivados de benzofuran-piperidina
PE20121087A1 (es) Compuestos antiproliferativos, conjugados de los mismos, procedimientos para estos, y usos de los mismos
CO5640152A2 (es) Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c
PE20141726A1 (es) Heterociclilaminas como inhibidores de pi 3k
AR045761A1 (es) Derivados de 2-piridona como inhibidores de elastasa de neutrofilos
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
AR037754A1 (es) Herbicidas
AR069796A1 (es) Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen
AR060875A1 (es) Derivados de 2-piridona como inhibidores de la neutrofilo elastasa humana
AR076563A1 (es) Derivados de ciclopenta[c]pirrol-2-carboxilatos, su preparacion y su apli-cacion en terapeutica
AR064889A1 (es) Derivados de piridopirimidinas, un metodo para su preparacion, una composicion y un producto farmaceutico que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por pde-4
AR070648A1 (es) Derivados de bencimidazol sustituido
AR058383A1 (es) Carboxamidas procedimientos para su obtencion y sus usos
AR059521A1 (es) Ariltienopirimidinas sustituidas con azaciclilo, procedimiento para su preparacion y su uso como medicamentos

Legal Events

Date Code Title Description
FG Grant, registration